

Presented by Dr Katie Wickenden Haematology ST6 University Hospitals of Leicester NHS Trust

The Leeds Teaching Hospitals



Case 5

- 83 year old male presenting with pancytopenia
- PMH: Non-Hodgkins lymphoma (DLBCL on background of follicular lymphoma)
- Haemoglobin 74 g/dL
- Platelet count 128 x10⁹/L
- White cell count 3.2 x10⁹/L
- Neutrophil count 0.37 x10⁹/L





















Marked erythroid dysplasia







Bone marrow trephine (low power)





Bone marrow trephine (high power)





What further testing would you next request based on the morphology?

- a) Myeloid NGS panel
- b) Perls' stain on aspirate
- c) Karyotype
- d) FISH for BCR ABL
- e) Reticulin stain on trephine



Bone marrow aspirate (high power)



Perls' stain demonstrating ring sideroblasts at >15%



Bone marrow aspirate (high power)





What cytogenetic or molecular abnormalities could you expect to find?

- a) Deletion of the long arm of chromosome 5
- b) BCR ABL
- c) SF3B1mutation
- d) TP53 mutation
- e) ASXL1 mutation





Molecular results

- No pathogenic or likely pathogenic variants detected by NGS myeloid gene panel
- Variant of uncertain significance (VUS) in MPL and NOTCH1



Cytogenetic results

- Del Y in all 10 cells
- One other abnormality, confirmed by FISH testing



FISH BCR ABL





45,X,-Y,t(9;22)(q34;q11)[10] BCR::ABL1 rearranged [92%] by interphase FISH

Images courtesy of Karen Marshall, department of cytogenetics University Hospitals of Leicester.



Bone marrow trephine (high power)





What is the final diagnosis?

a) Therapy related myelodysplasia with multilineage dysplasia

b) Myeloid neoplasm (myelodysplasia with multi-lineage dysplasia) post cytotoxic therapy (MN-pCT)

c) MDS/MPN U

- d) MDS with low blasts and ring sideroblasts
- e) MDS with low blasts and SF3B1 mutation
- f) Chronic myeloid leukaemia



Diagnosis

- 'Likely therapy related myelodysplasia with ring sideroblasts and BCR::ABL1'
- *WHO v4:* Therapy related myelodysplasia with multilineage dysplasia.
- *WHO v5:* Myeloid neoplasm (myelodysplasia with multi-lineage dysplasia) post cytotoxic therapy
- *ICC:* Therapy related myelodysplasia with multilineage dysplasia



Review of literature

- Keung et al (2004) undertook a retrospective study of 148 cases of t(9;22) (1)
 - 84% CML
 - 13% de novo ALL
 - 2% de novo AML
 - 3% MDS (de novo and treatment related)
- Chelapreddy et al (2018) presented a case and reviewed 22 case reports of Ph+ MDS (2)
 - 8 out of 15 cases (with data available) progressed to leukaemia
 - 8 patients received TKI, response variable
 - 1 patient had rising blast count on conventional chemotherapy but responded to imatinib



Literature & take home message

- A straight forward myelodysplastic neoplasm that wasn't what it seemed
- Rare cases of MDS with BCR ABL in the literature
- Prognostic implication of BCR ABL unknown but ?more likely to progress
- Role of TKI unknown



Acknowledgments

- Dr Angela Bowen (Northampton General Hospital)
- Dr Linda Barton (University Hospitals of Leicester)
- April Sellors (University Hospitals of Leicester)
- Karen Marshall (University Hospitals of Leicester)



References

- 1. <u>Philadelphia chromosome positive myelodysplastic syndrome</u> <u>and acute myeloid leukemia—retrospective study and review</u> <u>of literature – Keung et al - 2004 - Leukaemia Research</u>
- Philadelphia Translocation in MDS: A Case Report and a Brief Review of the Literature Looking at Its Prevalence, Disease Progression, and Treatment Options - Chelapareddy et al -2018 - Case Reports in Hematology - Wiley Online Library

